Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–137 of 137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: SHIELD Clear all

Conditions: Atrial Fibrillation
Interventions: MyTAP oral appliance plus mouth shield; Device
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obsessive Compulsive Behavior
Interventions: Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area, Transcranial Magnetic Stimulation: Sham, Exposure with Response Prevention; Device · Behavioral
Lead sponsor: Bradley Hospital; Other
Eligibility: 12 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Providence, Rhode Island

Conditions: Gastrointestinal Symptoms
Interventions: GlutenShield, Placebo; Dietary Supplement · Other
Lead sponsor: East Tennessee State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Hematologic Malignancy, Myeloid Malignancy
Interventions: Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan, Thiotepa; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cancer, Lymphoma
Interventions: Smart Phone Application-based Intervention - SHIELD, AION TempShield, Questionnaires; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 1 Year and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Cancer Screening, Colorectal Cancer (CRC)
Interventions: Cell free DNA (cfDNA) blood test, At home Fecal Immunochemical Test (FIT) or Colonoscopy; Device · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 45 Years to 75 Years
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia, Schizo Affective Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions: inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Hour to 1 Week
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lung Cancer, Breast Cancer, Prostate Cancer
Interventions: Radiotherapy; Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Pheochromocytoma, Paraganglioma
Interventions: 131 I-Metaiodobenzylguanidine (131 I-MIBG); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Coronary Artery Disease
Interventions: HeartMate PHP, Any Abiomed Impella® device approved for use in high-risk PCI; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 58
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 43 more

Conditions: Snoring
Interventions: DryMouth Shield; Device
Lead sponsor: VMS Medical Products, Inc; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Huntersville, North Carolina

Conditions: COVID-19, SARS-CoV 2
Interventions: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions: Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna; Drug · Radiation · Procedure
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 15 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 11
States / cities: Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more

Conditions: Holistic Care, Mental Health, Sleep, PTSD, Depression - Major Depressive Disorder, Anxiety, Resilience, Recovery, Occupation, Biometrics Measurement, Veteran, Quality of Life
Interventions: Not listed
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Acute Coronary Syndrome, Myocardial Infarction
Interventions: Magnetocardiography; Diagnostic Test
Lead sponsor: Genetesis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymphoma, Non-Hodgkin, ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia
Interventions: Graft Manipulation (CD34+ Selection); Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Effect of Oral Appliance Therapy on Atrial Fibrillation

TMS + Exposure Therapy for Pediatric OCD: Second Phase

Effects of GlutenShield, a Prebiotic, Probiotic, and Enzyme Supplement, on the Gut Microbiome of Adults With GI Symptoms

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

A Study Of Remote Patient Monitoring (RPM) Program For Cancer Patients Initiating Cancer-directed Therapy

Screening With a DNA Blood Test to Address Colorectal Cancer Inequities

Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia

Inhaled Nitric Oxide by Oxygen Hood in Neonates

Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

SHIELD II Clinical Investigation

The Effect of the DryMouth Shield on Snoring

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Using Integrated Care and Wearable Technology to Evaluate Outcomes of the Shields & Stripes Program for Veterans and First Responders

Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients

Preventing Stem Cell Transplant Complications With a Blood Separator Machine